Comparing Hypermarcas (OTCMKTS:HYPMY) & Traws Pharma (NASDAQ:TRAW)

Hypermarcas (OTCMKTS:HYPMY – Get Free Report) and Traws Pharma (NASDAQ:TRAW – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings and risk.

Institutional and Insider Ownership

8.0% of Traws Pharma shares are owned by institutional investors. 8.7% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Hypermarcas and Traws Pharma”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Hypermarcas $1.38 billion 1.97 $213.10 million $0.52 7.43
Traws Pharma $2.79 million 1.42 $9.17 million ($1.74) -0.15

Hypermarcas has higher revenue and earnings than Traws Pharma. Traws Pharma is trading at a lower price-to-earnings ratio than Hypermarcas, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Hypermarcas and Traws Pharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hypermarcas 0 1 0 1 3.00
Traws Pharma 1 4 0 0 1.80

Traws Pharma has a consensus target price of $1.00, suggesting a potential upside of 289.11%. Given Traws Pharma’s higher probable upside, analysts plainly believe Traws Pharma is more favorable than Hypermarcas.

Risk & Volatility

Hypermarcas has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.

Profitability

This table compares Hypermarcas and Traws Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Hypermarcas 20.07% 12.58% 7.00%
Traws Pharma N/A -23,868.92% -165.52%

Summary

Hypermarcas beats Traws Pharma on 10 of the 14 factors compared between the two stocks.

About Hypermarcas

(Get Free Report)

Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories. Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo QuĂ­mica and Mantecorp.

About Traws Pharma

(Get Free Report)

Traws Pharma is a clinical-stage biopharmaceutical company developing medicines for viral diseases and cancer. Its research includes antiviral candidates aimed at respiratory infections such as COVID-19 and influenza, as well as treatments for cancer. The company’s pipeline includes narazaciclib, an investigational CDK4/6 inhibitor being studied for cancer, and antiviral drug candidates designed to target SARS-CoV-2 and influenza. These products remain in development and are not established as approved treatments.

Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.